<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614336</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0478</org_study_id>
    <nct_id>NCT05614336</nct_id>
  </id_info>
  <brief_title>COVID-19 Antibody Responses in Cystic Fibrosis</brief_title>
  <acronym>CAR-CF</acronym>
  <official_title>Corona-Virus-Disease 2019 (Covid-19) Antibody Responses in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in&#xD;
      an ongoing global pandemic. It is unclear whether the relatively low number of reported cases&#xD;
      of COVID-19 in people with CF (pwCF) is due to enhanced infection prevention practices or&#xD;
      whether pwCF have protective genetic/immune factors. This study aims to prospectively assess&#xD;
      the proportion of pwCF, including both adults and children with CF who have evidence of&#xD;
      SARS-CoV-2 antibodies over a two-year period. This study will also examine whether pwCF who&#xD;
      have antibodies for SARS-CoV-2 have a different clinical presentation and what impact this&#xD;
      has on their CF disease. The proposed study will recruit pwCF from paediatric and adult CF&#xD;
      centres in Europe. Serological testing to detect antibodies will be performed on blood&#xD;
      samples taken at month 0, 6, 12, 18 and 24 with additional time-points if bloodwork is&#xD;
      available via normal clinical care. Clinical data on, lung function, CF-related medical&#xD;
      history, pulmonary exacerbations, antibiotic use, and microbiology and vaccination receipt,&#xD;
      will be collected during routine clinical assessments. Associations will be examined between&#xD;
      socio-demographic and clinical variables and serologic testing. The effects of SARS-CoV-2&#xD;
      infection on clinical outcomes and analyse end-points will be examined to explore any&#xD;
      age-related or gender-based differences, as well as subgroup analysis of outcomes in&#xD;
      lung-transplant recipients and pwCF receiving CFTR modulator therapies. As pwCF receive&#xD;
      COVID-19 vaccination a comparison of the development and progression of anti-SARS-CoV-2&#xD;
      antibodies in pwCF following natural infection and vaccination SARS-CoV-2 over time will be&#xD;
      performed&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2022</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-COV-2 seroprevalence</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of pwCF with at least 1 seropositive result over the study period and the difference in this proportion by age, geographical area and over time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of SARS-CoV-2 seropositivity, clinical symptoms and clinical outcomes in pwCF</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of symptomatic COVID-19 over the study period and severity; proportion of seropositive pwCF with subsequent CF exacerbation compared to pwCF who are seronegative; death rate in pwCF with at least one seropositive result compared to pwCF who are seronegative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal comparison of the detection including level and duration of anti-SARS-CoV-2 antibodies in pwCF following natural infection and SARS-CoV-2 vaccination</measure>
    <time_frame>2 years</time_frame>
    <description>Longitudinal comparison of the detection including level and duration of anti-SARS-CoV-2 antibodies in pwCF following natural infection and SARS-CoV-2 vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum proteomic and genomic responses of pwCF who are SARS-CoV-2 seropositive an seronegative</measure>
    <time_frame>10 years maximum</time_frame>
    <description>Serum proteomic and genomic responses of pwCF who are SARS-CoV-2 seropositive an seronegative</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cystic Fibrosis patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with cystic fibrosis, regardless of age, genetic profile, transplant status and disease severity will be eligible to participate in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)</description>
    <arm_group_label>Cystic Fibrosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Person with cystic fibrosis of any age, genotype, transplant status and disease&#xD;
             severity.&#xD;
&#xD;
          -  Express consent obtained after informing the patient and/or his legal representatives&#xD;
             or parents In France, written and informed consent will be requested.&#xD;
&#xD;
          -  For France, affiliation to a social security scheme or similar&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to give informed consent&#xD;
&#xD;
          -  Contraindication to venepuncture&#xD;
&#xD;
          -  For France&#xD;
&#xD;
               -  Person under guardianship / curatorship&#xD;
&#xD;
               -  Person under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Damian Downey, Dr</last_name>
    <phone>44 (0) 28 9032 9241</phone>
    <email>d.downey@qub.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>C.R.C.M. Pédiatrique (Centre de Ressources et de Compétences en Mucoviscidose) Hôpital des Enfants-Pellegrin - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pneumologie, allergologie et Mucoviscidose - CRCM Lyon pédiatrie Hôpital Femme Mère Enfant /Groupement Est</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe REIX, PU-PH</last_name>
      <phone>04.27.85.54.70</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.reix@chu.lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Ressources et de Competences de la Mucoviscidose (Enfants) CHU Grenoble Alpes - Hôpital Couple Enfant</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine LLERENA, Dr</last_name>
      <phone>04 76 76 93 83</phone>
      <phone_ext>+33</phone_ext>
      <email>CLlerena@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des maladies respiratoires Hôpital Arnaud de Villeneuve - CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaël CHIRON, Dr</last_name>
      <phone>04 67 33 60 89</phone>
      <phone_ext>+33</phone_ext>
      <email>r-chiron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de pédiatrie générale et spécialisée American Memorial Hospital - CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie - Centre cardio-pneumologie Hôpital Pontchaillou - CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chantal BELLEGUIC, Dr</last_name>
      <phone>02 99 28 24 78</phone>
      <phone_ext>+33</phone_ext>
      <email>chantal.belleguic@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRCM Pédiatrique Hôpital Sud - CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric DENEUVILLE, Dr</last_name>
      <phone>02 99 26 67 68</phone>
      <phone_ext>+33</phone_ext>
      <email>eric.deneuville@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ildys</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maladies respiratoires, allergologie - CRCM Mixte de Rouen Hôpital Charles Nicole - CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Service de pneumo-allergologie pédiatrique CRCM pédiatrique CHU de Toulouse - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie MITTAINE, Dr</last_name>
      <phone>05.34.55.87.37</phone>
      <phone_ext>+33</phone_ext>
      <email>mittaine.m@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Pneumologie-Allergologie CRCM adulte Hôpital Larrey - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marlène MURRIS-ESPIN, Dr</last_name>
      <phone>05 67 77 18 51</phone>
      <phone_ext>+33</phone_ext>
      <email>murris.m@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

